Search research articles
Contact Us
Filters
Showing results (201-210 of 227) with videos related to
Page
of 23
Sort By:
Nature Cancer
|
January 9, 2026
Suvemcitug plus chemotherapy in women with platinum-resistant recurrent ovarian cancer: the SCORES randomized, double-blinded, phase 3 trial
Guangwen Yuan, Ge Lou, Jundong Li, et al.
Carcinogenesis
|
June 11, 2014
MicroRNA-581 promotes hepatitis B virus surface antigen expression by targeting Dicer and EDEM1
Yu-Qun Wang, Yong-Feng Ren, Yi-Jiang Song, et al.
Journal of Ovarian Research
|
January 11, 2021
Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer
Zhen Yuan, Ying Zhang, Dongyan Cao, et al.
Carcinogenesis
|
September 27, 2018
MicroRNA-34a promotes MICB expression in hepatocytes
Meng-Tao Zhou, Chunming Zhao, Xiao Chen, et al.
Nucleic Acids Research
|
December 26, 2015
Dicer interacts with SIRT7 and regulates H3K18 deacetylation in response to DNA damaging agents
Pei-Ying Zhang, Guiling Li, Zhu-Jun Deng, et al.
JAMA Oncology
|
July 25, 2024
Bintrafusp Alfa for Recurrent or Metastatic Cervical Cancer After Platinum Failure: A Nonrandomized Controlled Trial
Michael Birrer, Guiling Li, Mayu Yunokawa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 22, 2022
Efficacy and Safety of the Anti-PD-L1 mAb Socazolimab for Recurrent or Metastatic Cervical Cancer: a Phase I Dose-Escalation and Expansion Study
Jusheng An, Jie Tang, Benjamin X Li, et al.
International Journal of Radiation Oncology, Biology, Physics
|
August 28, 2025
Dosimetric and Clinical Effects of Polyethylene Glycol Gel in Radical Concurrent Chemoradiotherapy for Cervical Cancer: A Phase III Prospective Multicenter Randomized Controlled Trial
Yuxuan Wang, Xiang Zhang, Fangfang Wang, et al.
Gynecologic Oncology
|
October 24, 2024
Phase II study of enlonstobart (SG001), a novel PD-1 inhibitor in patients with PD-L1 positive recurrent/metastatic cervical cancer
Guiling Li, Xiaofan Li, Rutie Yin, et al.
The Lancet. Oncology
|
June 2, 2020
Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study
Kunyu Yang, Yuhan Sheng, Chaolin Huang, et al.
Page
of 23
Search research articles
Search
Showing results (201-210 of 227) with videos related to
Sort By:
Page
of 23
Nature Cancer
|
January 9, 2026
Suvemcitug plus chemotherapy in women with platinum-resistant recurrent ovarian cancer: the SCORES randomized, double-blinded, phase 3 trial
Guangwen Yuan, Ge Lou, Jundong Li, et al.
Carcinogenesis
|
June 11, 2014
MicroRNA-581 promotes hepatitis B virus surface antigen expression by targeting Dicer and EDEM1
Yu-Qun Wang, Yong-Feng Ren, Yi-Jiang Song, et al.
Journal of Ovarian Research
|
January 11, 2021
Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer
Zhen Yuan, Ying Zhang, Dongyan Cao, et al.
Carcinogenesis
|
September 27, 2018
MicroRNA-34a promotes MICB expression in hepatocytes
Meng-Tao Zhou, Chunming Zhao, Xiao Chen, et al.
Nucleic Acids Research
|
December 26, 2015
Dicer interacts with SIRT7 and regulates H3K18 deacetylation in response to DNA damaging agents
Pei-Ying Zhang, Guiling Li, Zhu-Jun Deng, et al.
JAMA Oncology
|
July 25, 2024
Bintrafusp Alfa for Recurrent or Metastatic Cervical Cancer After Platinum Failure: A Nonrandomized Controlled Trial
Michael Birrer, Guiling Li, Mayu Yunokawa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 22, 2022
Efficacy and Safety of the Anti-PD-L1 mAb Socazolimab for Recurrent or Metastatic Cervical Cancer: a Phase I Dose-Escalation and Expansion Study
Jusheng An, Jie Tang, Benjamin X Li, et al.
International Journal of Radiation Oncology, Biology, Physics
|
August 28, 2025
Dosimetric and Clinical Effects of Polyethylene Glycol Gel in Radical Concurrent Chemoradiotherapy for Cervical Cancer: A Phase III Prospective Multicenter Randomized Controlled Trial
Yuxuan Wang, Xiang Zhang, Fangfang Wang, et al.
Gynecologic Oncology
|
October 24, 2024
Phase II study of enlonstobart (SG001), a novel PD-1 inhibitor in patients with PD-L1 positive recurrent/metastatic cervical cancer
Guiling Li, Xiaofan Li, Rutie Yin, et al.
The Lancet. Oncology
|
June 2, 2020
Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study
Kunyu Yang, Yuhan Sheng, Chaolin Huang, et al.
Page
of 23